Pharmaceutical giant AstraZeneca is set to inject £300 million into UK drug development after halting a £200 million expansion and vaccine plant last year.
The investment follows praise from drugmakers including AstraZeneca for a US-UK agreement aimed at increasing medicine prices in Britain in line with the Trump administration's new US pricing policies. The deal was finalised earlier in April.